Danny Rischin, MD

Danny Rischin, MD, discusses safety findings from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Danny Rischin, MD, discusses key DFS data from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the role of cemiplimab in the treatment of patients with cervical cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the next steps with cemiplimab (Libtayo) in the treatment landscape of cervical cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the use of cemiplimab (Libtayo) in patients with cervical cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses cemiplimab in cutaneous squamous cell carcinoma.